Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations

Wang Yang, Naifei Chen, Lingyu Li, Xiao Chen, Xiangliang Liu, Yongfei Zhang, Jiuwei Cui The Cancer Center of the First Hospital of Jilin University, Changchun, Jilin 130021, People’s Republic of ChinaCorrespondence: Jiuwei Cui Tel +86 431-8878-2178Fax +86-0431-88786134Email cuijw@jlu.edu.c...

Full description

Bibliographic Details
Main Authors:	Yang W, Chen N, Li L, Chen X, Liu X, Zhang Y, Cui J
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-09-01
Series:	Lung Cancer : Targets and Therapy
Subjects:	epidermal growth factor receptor (egfr) mutation tumor mutation burden (tmb) immune checkpoint inhibitor (ici) lung adenocarcinoma (luad).
Online Access:	https://www.dovepress.com/favorable-immune-microenvironment-in-patients-with-egfr-and-mapk-co-mu-peer-reviewed-article-LCTT

Similar Items

Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
by: Antonio Santaniello, et al.
Published: (2019-09-01)

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age
by: Yongfeng Wu, et al.
Published: (2020-04-01)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
by: Yuchun Niu, et al.
Published: (2020-08-01)

From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy
by: Andrea Sesma, et al.
Published: (2020-10-01)

Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma
by: Wang H, et al.
Published: (2021-05-01)

DNA Methylation Regulator-Meditated Modification Patterns Define the Distinct Tumor Microenvironment in Lung Adenocarcinoma
by: Didi Yuan, et al.
Published: (2021-09-01)

Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report
by: Katsuo Usuda, et al.
Published: (2020-06-01)

Rate of EGFR mutation in patients with pulmonary adenocarcinoma
by: Waqas Shuaib, et al.
Published: (2014-12-01)

Study Progression on Non-small Cell Lung Cancer with EGFR Mutation  Treated by Immune Checkpoint Inhibitors
by: Rilan BAI, et al.
Published: (2018-08-01)

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
by: Davide Bedognetti, et al.
Published: (2019-05-01)

MiRNA expression patterns are associated with tumor mutational burden in lung adenocarcinoma
by: Yufeng Lv, et al.
Published: (2019-10-01)

Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations
by: Song X, et al.
Published: (2017-06-01)

Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies
by: Anita Mazloom, et al.
Published: (2020-08-01)

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer
by: Chen Lin, et al.
Published: (2020-04-01)

Relationship between EGFR mutation and computed tomography characteristics of the lung in patients with lung adenocarcinoma
by: Xiaowei Qiu, et al.
Published: (2019-02-01)

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
by: Eun Young Kim, et al.
Published: (2018-12-01)

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
by: Xie Y, et al.
Published: (2021-10-01)

Nomogram based on preoperative CT imaging predicts the EGFR mutation status in lung adenocarcinoma
by: Guojin Zhang, et al.
Published: (2021-01-01)

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report
by: Eric Dansin, et al.
Published: (2015-03-01)

Identification of a Gene Signature Closely Related to Immunosuppressive Tumour Microenvironment Predicting Prognosis of Patients in EGFR Mutant Lung Adenocarcinoma
by: Jia Li, et al.
Published: (2021-09-01)

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
by: In Ae Kim, et al.
Published: (2018-07-01)

Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?
by: Hana Noskova, et al.
Published: (2020-01-01)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
by: Zhang R, et al.
Published: (2016-01-01)

Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression
by: Yiran Cai, et al.
Published: (2020-02-01)

Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation
by: Alexandre Schaller, et al.
Published: (2014-11-01)

Effect of EGFR-TKI on Lymphangiogenesis of Lung Cancer with EGFR Mutation
by: Minghui CAI, et al.
Published: (2014-12-01)

Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
by: Mary A. Wood, et al.
Published: (2020-03-01)

Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma
by: Zheng H, et al.
Published: (2019-07-01)

EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10)
by: Vázquez S, et al.
Published: (2016-02-01)

Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma
by: Hui ZHANG, et al.
Published: (2015-11-01)

EGFR-TKI plus bevacizumab as maintenance therapy for advanced lung adenocarcinoma: a retrospective study of 192 cases
by: HU Xueting, et al.
Published: (2021-04-01)

Predictive Role of EGFR Mutation Status on Postoperative Prognosis in Patients  with Resected Lung Adenocarcinomas
by: Hao BAI, et al.
Published: (2013-04-01)

Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma
by: Jiang WT, et al.
Published: (2018-03-01)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
by: Liang Shi, et al.
Published: (2021-03-01)

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis
by: Fei Chen, et al.
Published: (2020-06-01)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
by: Anna Maria Rachiglio, et al.
Published: (2019-03-01)

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
by: Chen D, et al.
Published: (2016-07-01)

Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma
by: Mingming Jia, et al.
Published: (2020-02-01)

Radiomics Signature as a Predictive Factor for EGFR Mutations in Advanced Lung Adenocarcinoma
by: Duo Hong, et al.
Published: (2020-01-01)

Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non–small cell lung carcinoma
by: Tripti Nakra, et al.
Published: (2021-07-01)

Cannot write session to /tmp/vufind_sessions/sess_fhghsen7o2vbtj9f26bqsrfdga